Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

📆 29-07-23 03:48:00
📰 Forbes

⏱ Reading Time:
15 sec. here
2 min. at publisher
📊 Quality Score:
News: 9%
Publisher: 53%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

Écrire un Commentaire

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
La source: Forbes - 🏆 394. / 53 Lire la suite »

Biogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
La source: WashTimes - 🏆 235. / 63 Lire la suite »